MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.
高成長
同社の収益は過去3年間にわたり着実に増加しており、年平均で154.47%の成長率を示しています。
高い利益成長
同社の純利益は業界をリードしており、最新の年間純利益はUSD 149.50Mです。
割安
同社の最新のPEは-3.33で、過去3年間の水準と比較して安値圏にあります。
機関投資家の売り越し
最新の機関投資家の保有株数は43.66M株で、前四半期比で38.54%減少しています。
市場活動が低調
同社への投資家の関心は低下しており、20日間の売買回転率は-0.10です。